The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

If you’ve been diagnosed with major depressive disorder or a form of anxiety, your mental health provider may prescribe the ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...